Plasma samples from MS cases tended to have higher levels of the neuroaxonal damage marker neurofilament light chain (NFL), chromogranin A (CHGA), Lysosomal Associated Membrane Protein 3 (LAMP3), interleukin‐17 receptor beta (IL17RB), interleukin 22 (IL22), insulin‐like growth factor binding protein 2 (IGFBP2), leukocyte immunoglobulin‐like receptor 4 (LILRB4), creatine kinase B (CKB), glial fibrillary acidic protein (GFAP), cathepsin F (CTSF), interleukin‐15 (IL15), MER proto‐oncogene tyrosine kinase (MERTK), and folate receptor alpha (FOLR1) than controls (Table 2, Table S1). This evidence concerns the gene IGFBP2 and myeloid sarcoma.